Recent advance in treatment and prognosis of gastrointestinal stromal tumors / 国际外科学杂志

ABSTRACT

Gastrointestinal stromal tumor(GIST) ,a kind of rare tumor,takes 1%～3% of all tumors in digestive tract,but are the most common in mesenehymal neoplasm.At present,the primal treatment of GIST is surgical operation,standard and rationality of surgery is the significant fatter that affects its curative effect.While imatinib is the main therapeutic tool for GIST that can' t benn resected or recurrence after operation.There is no definite circumscription between optimum and malignancy,there are many factors that influence the prognosis of GIST.We commonly apply Fletcher grading to evaluate the risk of GIST.